Patents by Inventor Aimee Cossins

Aimee Cossins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant clostridium botulinum neurotoxins
    Patent number: 10030238
    Abstract: The invention provides a nucleic acid sequence comprising a sequence of contiguous nucleotides, wherein said sequence of contiguous nucleotides has at least 90% sequence identity to the nucleic acid sequence of SEQ ID NO: 1, and wherein said sequence of contiguous nucleotides encodes a single-chain BoNT/E1 protein. The present invention also provides methods for producing soluble single-chain BoNT/E1 protein in an E. coli host cell, together with methods for producing soluble di-chain BoNT/E1 protein.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: July 24, 2018
    Assignees: IPSEN BIOINNOVATION LIMITED, IPSEN BIOPHARM LIMITED
    Inventors: Aimee Cossins, Matthew Beard, Philip Marks
  • RECOMBINANT CLOSTRIDIUM BOTULINUM NEUROTOXINS
    Publication number: 20150247139
    Abstract: The invention provides a nucleic acid sequence comprising a sequence of contiguous nucleotides, wherein said sequence of contiguous nucleotides has at least 90% sequence identity to the nucleic acid sequence of SEQ ID NO: 1, and wherein said sequence of contiguous nucleotides encodes a single-chain BoNT/E1 protein. The present invention also provides methods for producing soluble single-chain BoNT/E1 protein in an E. coli host cell, together with methods for producing soluble di-chain BoNT/E1 protein.
    Type: Application
    Filed: October 31, 2013
    Publication date: September 3, 2015
    Inventors: Aimee Cossins, Matthew Beard
  • Non-cytotoxic fusion proteins comprising EGF muteins
    Patent number: 8614069
    Abstract: The present invention relates to fusion proteins comprising a non-cytotoxic protease and a EGF mutein ligand. The EGF mutein provides improved EGF receptor activation for the claimed fusion proteins. Also provided is the use of said polypeptides as therapeutics for suppressing mucus hypersecretion, inflammation, endocrine neoplasia and/or neuroendocrine disorders, neuroendocrine tumors, for suppressing cancers such as colorectal cancer, prostate cancer, breast cancer, and lung cancer.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: December 24, 2013
    Assignee: Syntaxin Limited
    Inventors: Aimee Cossins, Ian Birch-Machin, Patrick Stancombe
  • NON-CYTOTOXIC FUSION PROTEINS COMPRISING EGF MUTEINS
    Publication number: 20110177056
    Abstract: The present invention relates to fusion proteins comprising a non-cytotoxic protease and a EGF mutein ligand. The EGF mutein provides improved EGF receptor activation for the claimed fusion proteins. Also provided is the use of said polypeptides as therapeutics for suppressing mucus hypersecretion, inflammation, endocrine neoplasia and/or neuroendocrine disorders, neuroendocrine tumours, for suppressing cancers such as colorectal cancer, prostate cancer, breast cancer, and lung cancer.
    Type: Application
    Filed: August 19, 2009
    Publication date: July 21, 2011
    Applicant: SYNTAXIN LIMITED
    Inventors: Aimee Cossins, Ian Birch-Machin, Patrick Stancombe